Cisplatin and ototoxicity in childhood: the perspective of supporting otoprotective agentes

A G F S Araujo1, J C Silva1, E M Trindade Filho1

  • 1Universidade Estadual de Ciências da Saúde de Alagoas - UNCISAL, Maceió, AL, Brasil.

Insights

This review identifies eight substances that can protect against cisplatin-induced hearing loss in children. These otoprotective drugs act as antioxidants, minimizing auditory damage and improving quality of life.

Area of Science:

  • Pharmacology and Toxicology
  • Oncology
  • Otolaryngology

Background:

  • Cisplatin is a vital antineoplastic drug used to treat various cancers.
  • A significant side effect of cisplatin is ototoxicity, leading to irreversible hearing loss, particularly impactful in pediatric patients due to its effect on language acquisition.
  • Minimizing cisplatin-induced ototoxicity requires identifying effective otoprotective drugs and optimal administration strategies.

Purpose of the Study:

  • To review and understand otoprotective drugs for preventive treatment against cisplatin-induced ototoxicity in childhood.
  • To assess the relevance and potential of these drugs in mitigating hearing loss.

Main Methods:

  • An integrative review was conducted using databases: PubMed, Bireme, MedLine, LILACS, SciELO, and ClinicalTrials.gov.
  • Search strategy involved crossing DeCS and MeSH descriptors with free terms.
  • Studies in English, Spanish, and Portuguese, with no publication year restrictions, were selected based on inclusion/exclusion criteria, resulting in 12 articles for full analysis.

Main Results:

  • Eight substances demonstrated potential otoprotective effects against cisplatin-induced ototoxicity: Amifostine, Dexamethasone, Genistein, Ginkgo Biloba, Lycopene, N-acetylcysteine, Polydatin, and Sodium Thiosulfate.
  • These drugs are administered via intravenous, oral, or transtympanic routes, before, during, or after cisplatin infusion.
  • Biochemical mechanisms include inactivation of oxygen free radicals and electrophilic platinum species, acting as antioxidant therapy.

Conclusions:

  • The identified substances show promise in reducing cisplatin-induced ototoxicity and subsequent hearing loss in children.
  • Otoprotective strategies can significantly improve the quality of life for pediatric cancer patients undergoing cisplatin treatment.
  • Further research into optimal drug combinations and administration protocols is warranted.